

CURRICULUM VITAE

General information

Personal details

Name: Tamar Nijsten
Gender: Male
Date of birth: 6-11-1972
Place of birth: Nijmegen, The Netherlands
Address: Albert Grisarstraat 20
2018 Antwerp, Belgium
Telephone: 00 31 (0)10 7031019 (work)
00 31 (0)6 81351995 (cell)
Fax: 00 31 (0)10 7033822
Email: t.nijsten@erasmusmc.nl

Academic education and degrees

University: University of Antwerp: highest award
Date: 1999; 7th year
* 1st price of the medical faculty 1999.
* Internship: 01-06-1998 till 30-09-1998, Rochester, NY, USA.

Doctorate

University: University of Antwerp, Faculty of medicine,
Date: 22 November 2004
Supervisor(s): Prof. dr. J. Lambert, University of Antwerp, Belgium
Prof. dr. R.S. Stern, Harvard Medical School, USA
Title of thesis: 'Global evaluation of long term treatments of psoriasis'

Work experience since graduation

Date: 01-10-1999 till 30-09-2005
Contract: Fixed-term, fulltime
Position: Dermatology residency University Hospital Antwerp, Prof. dr. J. Lambert

Date: 01-10-2000 till 30-6-2002
Contract: Fixed-term, fulltime
Position: Research fellow, Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School, Boston, USA, Prof. dr. R.S. Stern

Date: 01-07-2002 till 30-09-2005
Contract: Fixed-term, fulltime
Position: Research fellow Dermatology University Hospital Antwerp (Fund for Scientific Research Flanders), Prof. dr. J. Lambert

Date: 01-10-2005 till now:
Contract: Permanent, 0.6 fte
Position: Faculty member, Department of Dermatology, Erasmus MC, Rotterdam, The Netherlands, Prof. M. Neumann. (Since 2009; Associate Professor and since 2012; Professor in dermatology in particular epidemiology and social aspects)

Date: 01-10-2005 till 01-01-2006
Contract: Permanent, 0.4 fte
Position: Dermatology Clinic Antwerp, Antwerp, Belgium

Date: 01-01-2006 till 01-01-2007
Contract: Fixed, 0.4 fte
Position: Department of Dermatology, Hospital Walcheren Vlissingen, The Netherlands

Date: 01-01-2007 till 31-12-2010
Contract: Permanent, 0.4 fte
Position: Department of Dermatology, Amphia Hospital, Breda, The Netherlands

Date: 01-01-11 till 01-03-12
Contract: Permanent, 0.4 fte
Position: Mohs clinics, Dordrecht and Amsterdam, The Netherlands

Date: 01-03-12 till now
Contract: Permanent, 0.2 fte
Position: Mohs clinics, Dordrecht and Amsterdam, The Netherlands

Research

Brief summary of research over the last five years

After defending my thesis, I continued exploring data from the PUVA Follow Up Study (Harvard Medical School) to study the (carcinogenic) effects of ultraviolet therapy and the impact of psoriasis. In collaboration with Italian researchers, psychometric properties of quality of life measures were studied. The association between psoriasis and other comorbidities using data from a pharmacy database was also studied. A ZonMw grant (2008) enabled us to design a comparative randomized controlled trial (RCT) of two biologicals in the treatment of psoriasis.

Different therapies for varicose veins were compared in a meta-analysis. The recruitment of a multicentric RCT of 240 phlebological patients to compare surgery vs minimal invasive techniques has recently been completed. Together with physicists of the Technical University of Eindhoven, the mechanisms of endovenous laser therapy are studied to optimize patient care.

The PHARMO dataset was analyzed to study the effects of different drug classes on the development of melanoma in collaboration with pharmacists from LUMC. Together with Comprehensive Cancer Registry South and department of Public Health (Erasmus MC), epidemiological studies of skin cancer have been performed and are ongoing with a focus on gender differences in melanoma survival. In 2009, a second ZonMw grant was obtained to assess the prevalence of BCC and actinic keratosis in the general population. As part of this proposal, in 2010, we started to actively participate in the Rotterdam Study. Members of the cohort will receive a skin check and several technical investigations (3D photograph and spectrophotometer) with a focus on skin cancer incidence. In 2010, a Vidi grant enabled us to expand the research group and to focus on the genetic (epidemiological) component of skin cancer, especially among patients who develop multiple skin cancers. In addition of the genetic epidemiology of skin cancer, we expanded our interest to skin ageing and photodamage with the Netherlands Consortium of Healthy Ageing (NCHA).

Thesis supervision

Co-supervisor:

- Marlies Wakkee. Comorbidities in psoriasis. Erasmus MC 2010
- Els Koomen. Effect of drugs on melanoma. LUMC 2010
- Renate van den Bos. Endovenous therapies for varicose veins. Erasmus MC. 2011
- Cynthia Holterhues. Impact of melanoma in the Netherlands. Erasmus MC. 2011
- Sophie Flohil. Epidemiology of (multiple) basal cell carcinoma. Erasmus MC 2012

Supervisor:

- Arjen Joesse. Gender differences in melanoma survival. Erasmus MC
- Martijn Visser. Cost effectiveness analysis in treatment of psoriasis. Erasmus MC
- Emilia Dowlatshahi. Comorbidities in psoriasis. Erasmus MC
- Robert van der Leest. Epidemiology of multiple skin cancers. Erasmus MC
- Anke Biemans. Impact of varicose veins. Erasmus MC 2013.
- Loes Hollestein. Chemoprevention in keratinocytic malignancies. Erasmus MC 2013
- Anna-Christa de Vries. Biologicals in the management of psoriasis. AMC

- Cathelijne Bik. Off label use of drugs in dermatology. AMC
- Joris Verkouteren. Genetic epidemiology of multiple skin cancers. Erasmus MC
- Satu Siiskonen. Genetic and life style factors of squamous cell carcinoma. Erasmus MC
- Leonie Jacobs. Genetics of skin ageing and photodamage. Erasmus MC
- Merel Hamer. Skin aging in the general population. Erasmus MC.
- Rik Waalboer. Quality of life in patients with keratinocytic cancer. Erasmus MC.
- Ella van der Voort. Liver disease in patients with psoriasis. Erasmus MC.
- Enes Hajderbegovic. Role of atopy in other skin diseases. Erasmus MC
- Shmaila Talib. Exome sequencing in basal cell carcinoma patients. Erasmus MC.

Grant allocation

- Fonds L. Craeybeckx, F. Detiège, F. Grootjans, v.z.w., 1998 (10 k€).
- Fulbright scholarship 2001 (40 k\$)
- Research assistant of the Fund for Scientific Research–Flanders (Belgium) (F.W.O.-Vlaanderen), 2001 (60 k€).
- Research assistant of the Fund for Scientific Research–Flanders (Belgium) (F.W.O.-Vlaanderen), 2003 (60 k€).
- EORTC fellowship 2008 (100 k€). Gender differences in melanoma survival.
- Unrestricted Grant Wyeth 2007 (120 k€). Comorbidities in psoriasis.
- Unrestricted grant Meda Pharma 2008 (110 k€). Patient-reported outcomes in the treatment of actinic keratosis and basal cell carcinoma with topical imiquimod.
- Unrestricted grant Abbott 2009 (120 k€). Comorbidities in psoriasis.
- ZonMW doelmatigheidstudie 'dure geneesmiddelen'. An independent prospective randomised controlled trial comparing the efficacy and cost effectiveness of infliximab and etanercept in 'high need' patients with moderate to severe chronic plaque type psoriasis (2008/04238/ZONMW; principal investigators: T Nijsten & PI Spuls; 289 k€)
- ZonMW doelmatigheidstudie 'dure geneesmiddelen'. Basal cell carcinoma and actinic keratoses in the Netherlands: how often do they occur and who are at risk? (2009/16253/ZONMW; principal investigators: T Nijsten & E. de Vries ; 295 k€)
- Vidi 'Genetics of multiple basal cell carcinoma' (2010/91711315/ZONMW; 800 k€)
- Netherlands Consortium of Healthy Aging (NCHA) – Unilever. 'Genetic association studies on perceived age and age related visible traits' (2010; principal investigators: T Nijsten & M. Kayser; 400 k€)
- Prevalence and determinants of facial skin aging (2013; principal investigators: T Nijsten & M. Kayser; Unilever; 350 k€)

International research visits › 1 month

Date: 01-10-2000 till 30-6-2002
Contract: Fixed-term, fulltime
Position: Research fellow, Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School, Boston, USA, Prof. dr. R.S. Stern

Patents

-

Brief summary of teaching over the last five years

I participate in the teaching and training of medical students and dermatology residents at the Erasmus MC. I have served as chair for one of national residency education sessions and have been a speaker at several of these sessions (COCOM education). Currently, I supervise more than 10 PhD-projects of which most at the department of Dermatology, but also at the department of Public Health of the Erasmus MC and at the department of dermatology at Amsterdam Medical Center. In 2012, we were invited by the scientific and clinical dermatology societies of Europe (EADV and ESDR) to organize a fully funded 5-day summer course on clinical research and dermatology-epidemiology for a group of residents from 30 countries. I have been involved at many (inter)national dermatology meetings as organiser, scientific board member and/or invited speaker.

Managing / Coördinating

At a local level, I manage a research group of more than 10 people and am responsible for the phlebological care at the department of dermatology. Also, I serve on the scientific committee of our department and am since 2012 vice chair of the department of dermatology.

At a national level, I have been on the board of the Dutch Society of Dermatology and Venereology (NVDV) for several years and am the chair of this organization since 2012. Prior to chairing the NVDV, I served on the oncology and inflammatory dermatoses specialty groups of this organisation and contribute(d) to the development of national psoriasis and cutaneous squamous cell carcinoma guideline. In addition, I chair the board of the SSH, which is a foundation that serves the Dutch Society of Dermatology and Venereology, Skin Fund and Skin federation (Huidfederatie). I have also chaired the Advisory Council of the Dutch Skin Fund (Huidfonds).

Internationally, I chair the Quality of Life Task Force of the European Association of Dermatology and Venereology and am a member of the Phlebology task force. In the European Dermato-Epidemiology Network (EDEN), I chaired the executive group between 2010-2012 and now serve on its board.

I am on the board of directors of the Mohs clinics. This is a private dermatology clinic and has sites in Dordrecht, Hoorn and Amsterdam.

Lecturing

I have given over 100 lectures at (inter)national dermatology meetings. I have been an invited lecturer Dutch Society of Dermatology and Venereology, Swedish Society of Dermatology, Scottish Society of Dermatology, European Association of Dermatology and Venereology and European Society of Dermatological Research and several international subspecialty meetings.

Size (fte) and composition own research group

Head research team: dermatologist (Professor; 0.6 fte)

Supervisors: - Epidemiologist (Assistant Professor; 0.6 fte)
- Pharmacist (1.0 fte)

PhD students: - internal: 9 (7.0 fte; 5 physicians, one pharmacist and one biomedical scientist)
- external: 3 (3.0 fte; 3 physicians)

Patient Care

Brief summary of patient care over the last five years

In the last five years, I have performed patient care for 2 to 3 days weekly. My clinical activities are divided between the Erasmus MC where I supervise phlebological (ultrasound examination, surgery and endovenous therapies) and non academic setting. Between 2006-2012, I practiced at Amphia Hospital Breda and since 2010, I see patients in Mohs clinics Dordrecht.

Memberships

Editorial Board

Editorship:

- Associate editor: *J Invest Dermatol* (IF: 6.30; nr. 1 journal in dermatology) between 2008-2012
- Section editor (clinical research, health sciences & epidemiology). *J Invest Dermatol* (IF: 6.30; nr. 1 journal in dermatology) between 2012- now
- Section editor: *NTVG*

Occasional reviewer for:

- ZonMw
- Fonds voor Wetenschappelijk Onderzoek (FWO)-Vlaanderen
- French National Centre for Scientific Research
- British Council
- KWF
- Lancet
- N Engl J Med
- JAMA
- Many international dermatology and non-dermatology Journals

Professional society and/or committee

Membership:

- Society of Investigative Dermatology (SID)
- European Academy of Dermatology & Venereology (EADV)
- Dutch Society of Dermatology & Venereology (NVDV)
- Benelux Society of Phlebology
- International Dermatoepidemiology Association (IDEA)
- European Dermatoepidemiology Network (EDEN)
- ZonMW commission GGG (goed gebruik geneesmiddelen)
- ZonMW commission MKMD (meer kennis minder dieren)

Board member:

- Chair of the Dutch Society of Dermatology and Venereology (NVDV).
- Chair executive Committee. European Dermato-Epidemiology Network (EDEN)
- Treatment of psoriasis. European Dermatology Foundation.
- Taskforce: squamous cell carcinoma. Dutch Society of Dermatology and Venereology
- Taskforce: inflammatory dermatoses. Dutch Society of Dermatology and Venereology
- Treatment of psoriasis guideline committee. Dutch Society of Dermatology and Venereology
- Chair Taskforce: Quality of Life in dermatology. European Academy of Dermatology and Venereology
- Member of Taskforce: Phlebology. European Academy of Dermatology and Venereology
- Chair of Advisory Council Skin Fund (Huidfonds), The Netherlands
- Management team Rotterdam Study
- Psoriasis international Network (PIN)

Societal quality of own research

Adding to the existing work of prof. dr. R.S. Stern demonstrating the carcinogenic effects of PUVA has resulted in a substantial decrease of PUVA use in dermatology in the last decade. Following this experience with phase IV trials, I have raised the awareness of pharmacovigilance in dermatology.

The meta-analysis of endovenous therapies for varicose veins has assisted in gaining official reimbursement of these procedures in The Netherlands. Also, for the treatment of varicose veins, I have assisted in the scientific introduction of the steam ablation.

Describing the burden of skin cancer in The Netherlands has helped administrators and health technicians in several decision making processes.

Scholarships and prizes

- 1st Specia price Medical Faculty University of Antwerp, July 1999
- Fulbright research scholarship, 2001
- Roche Dermatology Prize 2003, Young Researcher Award. 'Prevention of (non)melanoma skin cancer'
- Euroderm Excellence Program, Rome 2004
- Roche Dermatology Prize 2005, Fundamental Research Award. 'Global evaluation of long term treatments of psoriasis'
- Pfizer Educational Prize of the Faculty of Medicine, University of Antwerp, 2005
- Pfizer Research Prize of the Faculty of Medicine, University of Antwerp, 2005. 'Global evaluation of psoriasis: prevalence, impact and its measurements, and treatments'
- Vidi ZonMw 2010
- Talent extraordinary, earasmus University Rotterdam, Vidi 2010

External consultancies (government / industry)

- I have reviewed research proposals for ZonMw, FWO-Flanders en centre National de la Research Scientifique (CNRS).
- I am part of the ZonMw commissions 'meer kennis minder dieren' en 'goed gebruik geneesmiddelen'.
- I have been an external consultant for the Federa Foundation.


- I have served on several (inter)national consultancy boards for the pharmaceutical industry, including: Abbott, Celgene, Galderma, Leo Pharma, MSD and Wyeth-Pfizer.

Publications


Person-years of research

- Harvard medical School (2001-2002):	2 years (1.0 fte)
- University of Antwerp (2003-2004):	2 years (1.0 fte)
- Erasmus University (2005-now):	8 years (0.5 fte)
Total:	8.5 years

Published Items in Each Year (May 2013)



Citations in Each Year (May 2013)



Analysis 'nijsten t*' Web of Science (May 2013)

Results found in Web of Science:	153
Sum of the Times Cited:	1895
Sum of Times Cited without self-citations:	1723
Citing Articles:	1504
Citing Articles without self-citations:	1425
Average Citations per Item:	12.39
h-index :	22

Publications

- Hajdarbegovic E, Thio B, Nijsten T. Lower lifetime prevalence of atopy in rheumatoid arthritis. *Rheumatol Int.* 2013 May 26. [Epub ahead of print] PubMed PMID: 23708584.
- Joose A, Collette S, Suci S, Nijsten T, Patel PM, Keilholz U, Eggermont AM, Coebergh JW, de Vries E. Sex Is an Independent Prognostic Indicator for Survival and Relapse/Progression-Free Survival in Metastasized Stage III to IV Melanoma: A Pooled Analysis of Five European Organisation for Research and Treatment of Cancer Randomized Controlled Trials. *J Clin Oncol.* 2013 May 20. [Epub ahead of print] PubMed PMID: 23690423.
- Waalboer-Spuij R, Nijsten TE. A review on quality of life in keratinocyte carcinoma patients. *G Ital Dermatol Venereol.* 2013 Jun;148(3):249-54. PubMed PMID: 23670061.
- van der Leest RJ, Nijsten T, de Vries E. Screening for second primary melanomas: is it efficient? Reply from authors. *Br J Dermatol.* 2013 May;168(5):1135. doi: 10.1111/bjd.12139. PubMed PMID: 23614564.
- Flohil SC, van der Leest RJ, Arends LR, de Vries E, Nijsten T. Risk of subsequent cutaneous malignancy in patients with prior keratinocyte carcinoma: A systematic review and meta-analysis. *Eur J Cancer.* 2013 Apr 19. doi:pii: S0959-8049(13)00212-8. 10.1016/j.ejca.2013.03.010. [Epub ahead of print] PubMed PMID: 23608733.
- van der Velden SK, Biemans AA, Nijsten T, Sommer A. Translation and validation of the Dutch VEINES-QOL/Sym in varicose vein patients. *Phlebology.* 2013 Apr 4. [Epub ahead of print] PubMed PMID: 23559592.
- Holterhues C, Hollestein LM, Nijsten T, Koomen ER, Nusselder W, de Vries E. Burden of disease due to cutaneous melanoma increased in the Netherlands since 1991. *Br J Dermatol.* 2013 Mar 29. doi: 10.1111/bjd.12346. [Epub ahead of print] PubMed PMID: 23551191.
- Dowlatshahi EA, van der Voort EA, Arends LR, Nijsten T. Markers of systemic inflammation in psoriasis: a systematic review and meta-analysis. *Br J Dermatol.* 2013 Apr 1. doi: 10.1111/bjd.12355. [Epub ahead of print] PubMed PMID: 23550658.
- Dowlatshahi EA, Wakkee M, Herings RM, Hollestein LM, Nijsten T. Increased Antidepressant Drug Exposure in Psoriasis Patients: A Longitudinal Population-based Cohort Study. *Acta Derm Venereol.* 2013 Mar 25. doi: 10.2340/00015555-1566. [Epub ahead of print] PubMed PMID: 23529077.
- Flohil SC, van der Leest RJ, Dowlatshahi EA, Hofman A, de Vries E, Nijsten T. Prevalence of Actinic Keratosis and Its Risk Factors in the General Population: The Rotterdam Study. *J Invest Dermatol.* 2013 Mar 19. doi: 10.1038/jid.2013.134. [Epub ahead of print] PubMed PMID: 23510990.
- Siiskonen SJ, Koomen ER, Visser LE, Herings RM, Guchelaar HJ, Ch Stricker BH, Nijsten TE. Exposure to phototoxic NSAIDs and quinolones is associated with an increased risk of melanoma. *Eur J Clin Pharmacol.* 2013 Mar 8. [Epub ahead of print] PubMed PMID: 23471440.
- Liu L, Soerjomataram I, Nijsten T, van der Aa M, van der Leest R, Coebergh JW, de Vries E. Trends in the risks of melanoma as a second primary cancer among cancer patients in the Netherlands, 1989-2008. *Melanoma Res.* 2013 Jun;23(3):206-12.
- van Akkooi AC, Nijsten T. A costly revolution for a subgroup of patients with metastatic melanoma. *Br J Dermatol.* 2013 Mar;168(3):467-70; discussion 470-1.
- Prinsen CA, de Korte J, Augustin M, Sampogna F, Salek SS, Basra MK, Holm EA, Nijsten TE; The EADV Taskforce on Quality of Life. Measurement of health-related quality of life in dermatological research and practice: outcome of the EADV Taskforce on Quality of Life. *J Eur Acad Dermatol Venereol.* 2013 Jan 9. doi: 10.1111/jdv.12090. [Epub ahead of print] PubMed PMID: 23301583.

Flohil SC, Seubring I, van Rossum MM, Coebergh JW, de Vries E, Nijsten T. Trends in Basal cell carcinoma incidence rates: a 37-year Dutch observational study. *J Invest Dermatol.* 2013 Apr;133(4):913-8.

Teulings HE, Overkamp M, Ceylan E, Nieuweboer-Krobotova L, Bos JD, Nijsten T, Wolkerstorfer AW, Luiten RM, van der Veen JP. Decreased risk of melanoma and nonmelanoma skin cancer in patients with vitiligo: a survey among 1307 patients and their partners. *Br J Dermatol.* 2013 Jan;168(1):162-71.

Nijsten T. [Tender love and care do not heal all wounds]. *Ned Tijdschr Geneeskd.* 2012;156(45):A5464.

Jacobs LC, Wollstein A, Lao O, Hofman A, Klaver CC, Uitterlinden AG, Nijsten T, Kayser M, Liu F. Comprehensive candidate gene study highlights UGT1A and BNC2 as new genes determining continuous skin color variation in Europeans. *Hum Genet.* 2013 Feb;132(2):147-58.

Flohil SC, van Dorst AM, Nijsten T, Martino Neumann HA, Munte K. Mohs micrographic surgery for basal cell carcinomas: appropriateness of 'Rotterdam' criteria and predictive factors for three or more stages. *J Eur Acad Dermatol Venereol.* 2012 Oct 8. doi: 10.1111/j.1468-3083.2012.04696.x. [Epub ahead of print] PubMed PMID: 23039378.

Fallah Arani S, Waalboer Spuij R, Nijsten T, Neumann HA, Thio B. Enteric-coated mycophenolate sodium in psoriasis vulgaris: an open pilot study. *J Dermatolog Treat.* 2013 Jan 20. [Epub ahead of print] PubMed PMID: 22998609.

Joose A, Collette S, Suci S, Nijsten T, Lejeune F, Kleeberg UR, Coebergh JW, Eggermont AM, de Vries E. Superior Outcome of Women With Stage I/II Cutaneous Melanoma: Pooled Analysis of Four European Organisation for Research and Treatment of Cancer Phase III Trials. *J Clin Oncol.* 2012 Apr 30. [Epub ahead of print] PubMed PMID: 22547594.

Bos WE, Nijsten TE, de Jonge MJ, Hamberg AP. Topical Psoralen Plus UV-A Therapy for Tyrosine Kinase Inhibitor-Induced Hand-Foot Syndrome. *Arch Dermatol.* 2012 Apr;148(4):546-7.

Hollestein LM, de Vries E, Nijsten T. Trends of cutaneous squamous cell carcinoma in the Netherlands: Increased incidence rates, but stable relative survival and mortality 1989-2008. *Eur J Cancer.* 2012 Feb 16. [Epub ahead of print] PubMed PMID: 22342554.

Stern RS, Nijsten T. Going beyond associative studies of psoriasis and cardiovascular disease. *J Invest Dermatol.* 2012 Mar;132(3 Pt 1):499-501.

Lambert J, Dowlatshahi EA, de la Brassinne M, Nijsten T. A descriptive study of psoriasis characteristics, severity and impact among 3,269 patients: results of a Belgian cross sectional study (BELPSO). *Eur J Dermatol.* 2012 Mar-Apr;22(2):231-7.

Flohil SC, van Tiel S, Koljenović S, Jaanen-van der Sanden G, Overbeek LI, de Vries E, Nijsten T. Frequency of non-histologically diagnosed basal cell carcinomas in daily Dutch practice. *J Eur Acad Dermatol Venereol.* 2012 Jan 3. doi: 10.1111/j.1468-3083.2011.04407.x. [Epub ahead of print] PubMed PMID: 22211725.

Mols F, Thong MS, Vissers P, Nijsten T, van de Poll-Franse LV. Socio-economic implications of cancer survivorship: Results from the PROFILES registry. *Eur J Cancer.* 2012 Sep;48(13):2037-42.

Nijsten T. Dermatology life quality index: time to move forward. *J Invest Dermatol.* 2012 Jan;132(1):11-3.

Nijsten T, Stern RS. How epidemiology has contributed to a better understanding of skin disease. *J Invest Dermatol.* 2012 Mar;132(3 Pt 2):994-1002.

Flohil SC, Koljenović S, de Haas ER, Overbeek LI, de Vries E, Nijsten T. [Basal cell carcinoma: often more than one]. *Ned Tijdschr Geneeskd.* 2011;155(47):A4110.

Kockaert M, de Roos KP, van Dijk L, Nijsten T, Neumann M. Duplication of the great saphenous vein: a definition problem and implications for therapy. *Dermatol Surg*. 2012 Jan;38(1):77-82. doi: 10.1111/j.1524-4725.2011.02154.x. Epub 2011 Sep 14. Review. PubMed PMID: 22092751.

Holterhues C, van de Poll-Franse LV, de Vries E, Neumann HA, Nijsten TE. Melanoma patients receive more follow-up care than current guideline recommendations: a study of 546 patients from the general Dutch population. *J Eur Acad Dermatol Venereol*. 2011 Oct 31. doi: 10.1111/j.1468-3083.2011.04297.x. [Epub ahead of print] PubMed PMID: 22035105.

Hofman A, van Duijn CM, Franco OH, Ikram MA, Janssen HL, Klaver CC, Kuipers EJ, Nijsten TE, Stricker BH, Tiemeier H, Uitterlinden AG, Vernooij MW, Witteman JC. The Rotterdam Study: 2012 objectives and design update. *Eur J Epidemiol*. 2011 Aug;26(8):657-86.

Van Deurzen B, Ceulen RP, Tellings SS, VAN DER Geld C, Nijsten T. Polidocanol concentration and time affect the properties of foam used for sclerotherapy. *Dermatol Surg*. 2011 Oct;37(10):1448-55.

Flohil SC, Koljenović S, de Haas ER, Overbeek LI, de Vries E, Nijsten T. Cumulative risks and rates of subsequent basal cell carcinomas in the Netherlands. *Br J Dermatol*. 2011 Oct;165(4):874-81.

Spuls PI, Nijsten T. Survival in cancer patients hospitalized for psoriasis: a commentary. *Br J Dermatol*. 2011 Jul;165(1):1-2.

Wakkee M, de Vries E, van den Haak P, Nijsten T. Increased risk of infectious disease requiring hospitalization among patients with psoriasis: a population-based cohort. *J Am Acad Dermatol*. 2011 Dec;65(6):1135-44.

van Ruijven PW, van den Bos RR, Alazard LM, van der Geld CW, Nijsten T. Temperature measurements for dose-finding in steam ablation. *J Vasc Surg*. 2011 May;53(5):1454-6.

Hollestein LM, van den Akker SA, Nijsten T, Karim-Kos HE, Coebergh JW, de Vries E. Trends of cutaneous melanoma in The Netherlands: increasing incidence rates among all Breslow thickness categories and rising mortality rates since 1989. *Ann Oncol*. 2012 Feb;23(2):524-30.

Biemans AA, van der Velden SK, Bruijninx CM, Buth J, Nijsten T. Validation of the chronic venous insufficiency quality of life questionnaire in Dutch patients treated for varicose veins. *Eur J Vasc Endovasc Surg*. 2011 Aug;42(2):246-53.

Curiel-Lewandrowski C, Nijsten T, Gomez ML, Hollestein LM, Atkins MB, Stern RS. Long-Term Use of Nonsteroidal Anti-inflammatory Drugs Decreases the Risk of Cutaneous Melanoma: Results of a United States Case-Control Study. *J Invest Dermatol*. 2011 Mar 10. [Epub ahead of print] PubMed PMID: 21390049. (IF 5.25)

Joose A, de Vries E, Eckel R, Nijsten T, Eggermont AM, Hölzel D, Coebergh JW, Engel J. Gender Differences in Melanoma Survival: Female Patients Have a Decreased Risk of Metastasis. *J Invest Dermatol*. 2011;131(3):719-26. (IF 5.25)

Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, Franke J, Antoniou C, Arenberger P, Balieva F, Bylaite M, Correia O, Daudén E, Gisondi P, Iversen L, Kemény L, Lahfa M, Nijsten T, Rantanen T, Reich A, Rosenbach T, Segaert S, Smith C, Talme T, Volc-Platzer B, Yawalkar N. Definition of treatment goals for moderate to severe psoriasis: a European consensus. *Arch Dermatol Res*. 2010;303(1):1-10.

van den Bos RR, Neumann M, Nijsten T. Laser fibre stabs the catheter: a serious complication of endovenous laser ablation. *Phlebology*. 2010 Nov 4.

Flohil SC, de Vries E, van Meurs JB, Fang Y, Stricker BC, Uitterlinden AG, Nijsten T. Vitamin D-binding protein polymorphisms are not associated with development of (multiple) basal cell carcinomas. *Exp Dermatol* 2010;19:1103-5 (IF 3.26)

van den Bos RR, Milleret R, Neumann M, Nijsten T. Proof-of-principle study of steam ablation as novel thermal therapy for saphenous varicose veins. *J Vasc Surg*. 2011;53(1):181-6 (IF 3.77)

- Flohil SC, de Vries E, Neumann HAM, Coebergh JW, Nijsten T. Incidence, Prevalence and Future Trends of Primary Basal Cell Carcinoma in the Netherlands. *Acta Dermatol Venereol* 2010;19(12):1103-5 (IF 2.46)
- Husson O, Holterhues C, Nijsten T, Van de Poll-Franse LV. Melanoma survivors are dissatisfied with perceived information about their diagnosis, treatment and follow-up care. *Br J Dermatol* 2010; 163(4):879-81 (IF 3.49)
- Nijsten T, Bergstresser P. Patient advocacy groups in dermatology: let's stick together. *J Invest Dermatol* 2010;130:1757-9 (IF 5.25)
- Biemans AA, Van Den Bos RR, Nijsten T. Endovenous therapies of varicose veins: indications, procedures, efficacy and safety. *G Ital Dermatol Venereol*. 2010;145(2):161-73.
- van der Geld CW, van den Bos RR, van Ruijven PW, Nijsten T, Neumann HA, van Gemert MJ. The heat-pipe resembling action of boiling bubbles in endovenous laser ablation. *Lasers Med Sci*. 2010;25(6):907-9.
- Holterhues C, de Vries E, Louwman M, Koljenović S, Nijsten T. Incidence and trends of cutaneous malignancies in the Netherlands, 1989-2005. *J Invest Dermatol*, 2010;130:1807-12 (IF 5.25)
- Koomen ER, de Vries E, van Kempen LC, van Akkooy AC, Guchelaar HJ, Nijsten T, Coebergh JW. Epidemiology of extracutaneous melanoma in the Netherlands. *Cancer Epidemiol Biomarkers Prev*, in press 2010;19(6):1453-9 (IF 4.77)
- Joose A, de Vries E, van Eijck CH, Eggermont AM, Nijsten T, Coebergh JW. Reactive Oxygen Species and Melanoma: An Explanation for Gender Differences in Survival? *Pigm Cell Melanoma Res* 2010; 23(3):352-64 (IF 4.63)
- Kiiski V, de Vries E, Flohil SC, Bijl MJ, Hofman A, Stricker BH, Nijsten T. Risk factors for single and multiple basal cell carcinomas. *Arch Dermatol*, 2010 146(8):848-55 (IF 3.40)
- Holterhues C, Cornish D, van de Poll-Franse LV, Krekels G, Koedijk F, Kuijpers D, Coebergh JW, Nijsten T. Impact of melanoma on patients' lives among 562 survivors: a Dutch population based study. *Arch Dermatol*, 2011;147(2):177-85. (IF 3.40)
- De Haas ERM, Nijsten T, de Vries E. Population Education in Preventing Skin Cancer: From Childhood to Adult. *J Drugs Dermatol*, 2010; 9:112-6
- Poulsen ML, Spuls PI, Bos JD, Stern RS, Nijsten T. Quantative evaluation of clinical psoriasis severity measures: Results of a systematic review. *J Invest Dermatol*, 2010; 130:933-43 (IF 5.25)
- Mols F, Holterhues C, Nijsten T, van de Poll-Franse LV. Personality is associated with health status and impact of cancer among melanoma survivors. *Eur J Cancer*, 2010;46(3):573-80 (IF 4.48)
- Wakkee M, Herings RM, Nijsten T. Psoriasis May Not be an Independent Risk Factor for Acute Ischemic Heart Disease Hospitalizations: Results of a Large Population-Based Dutch Cohort. *J Invest Dermatol*. 2010;130(4):962-7. (IF 5.25)
- Koomen ER, Herings RM, Guchelaar HJ, Nijsten T. Melanoma incidence and exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. *Cancer Epidemiol*. 2009;33(5):391-5
- Frew JW, Martin LK, Nijsten T, Murrell DF. Quality of Life Evaluation in Epidermolysis Bullosa (EB) through the development of the QOLEB Questionnaire: an EB-Specific Quality of Life Instrument. *Br J Dermatol* 2009 ;161(6):1323-30 (IF 3.49)
- Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A, Barker J, Bos JD, Burmester GR, Chimenti S, Dubertret L, Eberlein B, Erdmann R, Ferguson J, Girolomoni G, Gisondi P, Giunta A, Griffiths C, Hönigsmann H, Hussain M, Jobling R, Karvonen SL, Kemeny L, Kopp I, Leonardi C, Maccarone M, Menter A, Mrowietz U, Naldi L, Nijsten T, Ortonne JP, Orzechowski HD, Rantanen T, Reich K, Reytan N, Richards H, Thio HB, van de Kerkhof P, Rzany B. European S3-guidelines on the

- systemic treatment of psoriasis vulgaris. *J Eur Acad Dermatol Venereol*. 2009;23 Suppl 2:1-70. (IF 2.28)
- Nijsten T, Spuls PI, Naldi L, Stern RS. The misperception that clinical trial data reflect long-term drug safety: lessons learned from Efalizumab's withdrawal. *Arch Dermatol*. 2009;145(9):1037-9. (IF 3.40)
- Langendoen SI, Habbema L, Nijsten T, Neumann HAM. Lipedema: from clinical presentation to therapy: a review of the literature. *Br J Dermatol*, 2009;161(5):980-6 (IF 3.49)
- van der Linden MW, Penning-van Beest FJ, Nijsten T, Herings RM. Topical corticosteroids and the risk of diabetes mellitus: a nested case-control study in the Netherlands. *Drug Saf*. 2009;32(6):527-37. (IF 3.54)
- Cornish D, Holterhues C, van de Poll-Franse LV, Coebergh JW, Nijsten T. A systematic review of health-related quality of life in cutaneous melanoma. *Ann Oncol*. 2009;20:vi51-8. (IF 4.94)
- Joose A, Koomen ER, Casparie MK, Herings RM, Guchelaar HJ, Nijsten T. Non-Steroidal Anti-Inflammatory Drugs and Melanoma Risk: Large Dutch Population-Based Case-Control Study. *J Invest Dermatol*. 2009; 129(11):2620-7 (IF 5.25)
- Nijsten T, Wakkee M. Complexity of the association between psoriasis and comorbidities. *J Invest Dermatol*. 2009;129(7):1601-3. (IF 5.25)
- Wakkee M, Neumann HAM, Herings R, van der Linden MH, Nijsten T. Psoriasis is not an independent predictor for the use of cardiovascular and antidiabetic drugs: Results from a five year prevalence comparison study using a pharmacy database. *Acta Dermatol Venereol* 2009; 89(5):476-83. (IF 3.00)
- Van den Bos RR, Wentel TD, Neumann M, Nijsten T. The treatment of incompetent perforating veins using the radiofrequency ablation stylet: a pilot study. *Phlebology* 2009;24(5):208-12 (IF 1.06)
- Koomen ER, Joosse A, Herings R, Casparie M, Guchelaar H, Nijsten T. Does use of estrogens decrease Breslow thickness of melanoma of the skin? *Melanoma Res* 2009;9(5):327-32 (IF 2.34)
- van Hattem S, Aarts MJ, Louwman WJ, Neumann HA, Coebergh JW, Looman CW, Nijsten T, de Vries E. Increase in basal cell carcinoma incidence steepest in individuals with high socioeconomic status: results of a cancer registry study in the Netherlands. *Br J Dermatol*. 2009;161(4):840-5. (IF 3.49)
- van der Wegen-Franken CP, Tank B, Nijsten T, Neumann HA. Changes in the pressure and the dynamic stiffness index of medical elastic compression stockings after having been worn for eight hours: a pilot study. *Phlebology*. 2009;24:31-7. (IF 1.06)
- Wakkee M, Nijsten T. Dermatology and comorbidities. *Dermatol Clin*, 2009;27:137-47, vi. (IF 1.69)
- Amzayyb M, van den Bos RR, Kodach VM, de Bruin DM, Nijsten T, Neumann HA, van Gemert MJ. Carbonized blood deposited on fibres during 810, 940 and 1,470 nm endovenous laser ablation: thickness and absorption by optical coherence tomography. *Lasers Med Sci*. 2010;25:439-47 (IF 1.68)
- van den Bos RR, Kockaert MA, Neumann HAM, Bremmer RH, Nijsten T, van Gemert MJC. Heat conduction from the exceedingly hot fiber tip contributes to endovenous laser ablation of varicose veins. *Laser Med Sci*. 2009;24:247-51. (IF 1.68)
- Nijsten T, van den Bos RR, Goldman MP, Kockaert MA, Proebstle TM, Rabe E, Sadick NS, Weiss RA, Neumann MH. Minimally invasive techniques in the treatment of saphenous varicose veins. *J Am Acad Dermatol*. 2009;60:110-9. (IF 4.08)
- Koomen ER, Joosse A, Herings R, Casparie M, Guchelaar H, Nijsten T. Oestrogens, oral contraceptives and hormonal replacement therapy increase the incidence of cutaneous melanoma: a population based case control study. *Ann Oncol*, 2009;20:358-64 (IF 4.94)

- Van den Bos RR, Kockaert MA, de Roos KP, Nemuann HAM, Nijsten T. Endovenous Laser Ablation induced complications: review of the literature and new cases. *Dermatol Surg*. 2009;35(8):1206-14. (IF 2.10)
- van den Bos R, Arends R, Kockaert M, Neumann M, Nijsten T. Endovenous therapies of lower extremity varicosities: a meta-analysis. *J Vasc Surg*. 2009;49:230-9. (IF 3.77)
- Nijsten T, Sampogna F, Abeni D. Categorization of Skindex-29 scores using mixture analysis. *Dermatology* 2009;218:151-4. (IF 2.23)
- de Leeuw J, van Lingen R, Both H, Nijsten T, Tank B, Neumann M. A comparative study on the efficacy of treatment with 585 nm Pulsed Dye Laser and Ultraviolet B-TL01 in plaque type psoriasis. *Dermatol Surg*, 2009;35:80-91 (IF 2.10)
- Nijsten T, Spuls PI. Adalimumab may be better or no worse than methotrexate in the treatment of psoriasis. *Br J Dermatol*. 2008;159:257-8. (IF 3.49)
- Nijsten T, Spuls PI, Stern RS. STROBE: a beacon for observational studies. *Arch Dermatol*, 2008;144:1200-4 (IF 3.40)
- Wakkee M, Lugtenberg M, Spuls PI, Thio B, de Jong EM, Guchelaar, Nijsten T. Knowledge, attitudes and use of the guidelines for the treatment of moderate to severe plaque psoriasis among Dutch dermatologists. *Br J Dermatol*, 2008;159:426-32. (IF 3.49)
- Nijsten T, Wakkee M. Psocare: Italy shows the way in postmarketing studies. *Dermatology*. 2008;217:362-364. (IF 2.23)
- de Vries E, Nijsten T, van Hattem S, Janssen-Heijnen M, Visser O, Schaapveld M, Eggermont AMM, Coebergh JW. Superior survival of female melanoma patients is independent of Breslow thickness, histologic type and tumor site: results from a Dutch general population cancer registry. *Ann Oncol*, 2008;19(3):583-9. (IF 4.94)
- van den Bos R, Kockaert MA, Neumann HAM, Nijsten T. Technical review of endovenous laser therapy for varicose veins. *Eur J Endovas Vasc Surg*, 2008;35(1):88-95. (IF 3.01)
- Wakkee M, Thio HB, Spuls PI, de Jong EM, Nijsten T. Evaluation of the reimbursement criteria for biological therapy for psoriasis in the Netherlands. *Br J Dermatol*, 2008;158:1159-61 (IF 3.49)
- Both H, Essink-Bot ML, Busschbach JJV, Nijsten T. Critical review of generic and dermatology specific health related quality of life instruments. *J Invest Dermatol*, 2007;127:2726-39.(IF 5.25)
- Koomen ER, Joesse A, Herings RMC, Bergman W, Nijsten T, Guchelaar HG. Effect of statins on melanoma of the skin. *Eur J Cancer*, 2007;43:2580-9. (IF 4.48)
- Nijsten T, De Haas ERM, Neumann HAM. Question the obvious. *Arch Dermatol*. 2007;143:1429-32. (IF 3.40)
- Nijsten T, Meads D, de Korte J, Sampogna F, Gelfand JM, Ongenaes K, Evers A, Augustin M. Cross cultural inequivalence in dermatology specific health related quality of life instruments among psoriasis patients. *J Invest Dermatol*, 2007;127:2315-22. (IF 5.25)
- de Vries E, Houterman S, Janssen-Heijnen ML, Nijsten T, Eggermont AM, Coebergh JW. Up-to-date survival estimates and historical trends of cutaneous malignant melanoma in the south-east of The Netherlands. *Ann Oncol*, 2007;18:1110-6 (IF 4.94)
- Nijsten T, Sampogna F, Stern RS, Abeni D. The psychometric properties of the reduced version of the Impact of Psoriasis (IPSO) questionnaire in Italian patients. *Dermatology*, 2007;215:348-51. (IF 2.23)
- Nijsten T, Rombouts S, Lambert J. Acne is prevalent but use of its treatments is not among adolescents from the general population. *J Eur Acad Dermatol Venereol*, 2007;21:163-8. (IF 2.28)

- Rombouts S, Nijsten T, Lambert J. Cigarette smoking and acne in adolescents: a cross-sectional study. *J Eur Acad Dermatol Venereol*, 2007;21:326-33. (IF 2.23)
- Nijsten T, Looman CM, Stern RS. Clinical severity of psoriasis in last 20 years of PUVA study. *Arch Dermatol*, 2007;143:1113-21. (IF 3.40)
- Nijsten T. Level of AGREEment with the British guidelines of the biologicals in psoriasis management. *Arch Dermatol*, 2007;143:1567-9. (IF 3.40)
- Mentens G, Lambert J, Nijsten T. Polymorphic light eruption may be associated with cigarette smoking and alcohol consumption. *Photodermatol, Photoimm, Photomed*, 2006; 22:87-92. (IF 1.48)
- Nijsten T, Meads D, McKenna SP. Dimensionality of the Dermatology Life Questionnaire Index (DLQI): a commentary. [Letter] *Acta Derm Venereol*, 2006;86:284-285. (IF 2.25)
- Nijsten T, Sampogana F, Chren MM, Abeni D. Rasch analysis to test and shorten the Skindex-29: Skindex-17. *J Invest Dermatol*, 2006;126:1244-50. (IF 5.25)
- Unaeze J, Nijsten T, Murphy A, Ravichandran C, Stern RS. Impact of psoriasis on health related quality of life decrease over time: an 11-year prospective study. *J Invest Dermatol*, 2006 126:1480-9. (IF 5.25)
- Nijsten T, Lambert J. Dermatologists' views and opinions about photo(chemo)therapy and conventional systemic psoriasis therapies: results from a national survey in Belgium. *Dermatology*, 2006;213:123-33. (2.23)
- Gelfand J, Kist J, Nijsten T, Stern RS, Rolstad T, Feldman SR, Margolis DJ. The prevalence of psoriasis in African Americans: Results from a population based study. *J Am Acad Dermatol* 2005;52:23-6. (IF 4.08)
- Nijsten T, Whalley D, Gelfand J, Margolis DJ, McKenna SP, Stern RS. The psychometric properties of the Psoriasis Disability Index in United States patients. *J Invest Dermatol* 2005;125:665-72. (IF 5.25)
- Gelfand JM, Gladman DD, Mease P, Smith N, Margolis DJ, Nijsten T, Stern RS, Feldman SR, Rolstad, T. Epidemiology of Psoriatic Arthritis in the United States Population. *J Am Acad Dermatol* 2005;53:573. (IF 4.08)
- Nijsten T, Unaeze J, Stern RS. Refinement and reduction of the Impact of Psoriasis Questionnaire: Classical test theory vs Rasch analysis. *Br J Dermatol*, 2005;154:692-700. (IF 3.49)
- Nijsten T, Stern RS, Margolis DJ, Feldman SR, Rolstad T. Members of the National Psoriasis Foundation: more extensive disease and better informed about treatment options. *Arch Dermatol* 2005;141:19-26. (IF 3.40)
- Nijsten T, Margolis DJ, Feldman SR, Rolstad T, Stern RS. Traditional systemic treatments Have not fully met the needs of psoriasis patients: results from a national survey. *J Am Acad Dermatol* 2005;52:434-44. (IF 4.08)
- Nijsten T, Geluyckens E, Colpaert CG, Lambert J. Peroxisome proliferator activated receptors α , β and γ in squamous cell carcinoma and its precursors. *J Cut Pathol* 2005;32:340-7. (IF 1.56)
- Van de Voorde K, Nijsten T, Schelfout K, Moorkens G, Lambert J. Long term use of silver containing nose-drops resulting in systemic argyria. *Acta Clin Belgica*, 2005;60:33-5. (IF 1.28)
- Nijsten T, Leys C, Verbruggen K, Verlinden V, Drieghe J, Stas M, Lambert J, DeGreef H, Garmyn M. A case-control study to identify melanoma risk factors in the Belgian population: the significance of clinical examination. *J Eur Acad Dermatol Venereol*, 2005;19:332-9. (IF 2.28)

- Nijsten T, Lapière K, Lambert J. A Patient with Xeroderma Pigmentosum Treated with Imiquimod 5% Cream. *J Am Acad Dermatol*. 2005;52:170-1. (IF 4.08)
- Feldman SR, Nijsten T, Margolis DJ, Rolstad T. Systemic therapy does not usually clear psoriasis, but treatment success does not require clearing. *J Am Acad Dermatol*. 2005;52:140-1. (IF 4.08)
- Bracke A, Nijsten T, Meuleman L, Lambert J. Lansoprazole-induced subacute lupus erythematoses: 2 cases. *Acta Derm Venereol* 2005;85:353-4. (IF 2.25)
- Nijsten T, Curiel-Lewandrosky C, Kadin ME. Lymphomatoid papulosis in children: a retrospective cohort study of 35 cases. *Arch Dermatol* 2004;140:306-312. (IF 3.40)
- Stern RS, Nijsten T. Insuring Rapid and Robust Safety Assessment. *J Invest Dermatol* 2004;122: 857-8. (IF 5.25)
- Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. *J Invest Dermatol Symp Proc* 2004;9:136-9 (IF 5.25)
- Mentens G, Nijsten T, Lambert J. Comment on "Recalcitrant tinea corporis as the presenting manifestation of patch-stage mycosis fungoides". [Letter] *Cutis* 2004;73:378 (IF 0.80)
- Nijsten T, Colpaert CC, Vermeulen PB, Harris AL, Van Marck E, Lambert J. Cyclooxygenase-2 expression and angiogenesis in squamous cell carcinoma of the skin and its precursors: a paired immunohistochemical study of 35 cases. *Br J Dermatol* 2004;151:837-45. (IF 3.49)
- Nijsten T, Stern RS. The increased risk of skin cancer is persistent after discontinuation of PUVA: a cohort study. *J Invest Dermatol* 2003;121:252-258. (IF 5.25)
- Nijsten T, Stern RS. Oral retinoid use reduces cutaneous squamous cell carcinoma risk in psoriasis patients treated with PUVA: a nested cohort study. *J Am Acad Dermatol* 2003;49:644-650. (IF 4.08)
- Nijsten T, De Moor A, Colpaert C, Roberts K, Mahieu L, Lambert J. Restrictive Dermatopathy: a case report and a critical review of all hypothesis of its origin. *Ped Dermatol* 2002;19:67-72.
- Nijsten T, Mentens G, Lambert J. Vascular variant of keratosis lichenoides chronica associated with hypothyroidism and response to tacalcitol and acitretin. *Acta Derm Venereol* 2002; 82:128-30. (IF 2.25)
- Nijsten T, Stern RS. Genital squamous cell carcinoma in men treated by photochemotherapy. A cancer registry-based study from 1978 to 1998. [Letter] *Br J Dermatol* 2002;147:184-5. (IF 3.49)
- Nijsten T, Meuleman L, Lambert J. Neutrophilic eccrine hidradenitis in patient with Behçet's disease. *Br J Dermatol* 2002;147:797-800. (IF 3.49)
- Nijsten T, Meuleman L, Schroyens W, Lambert J. Thalidomide-induced morbilliform rash: diagnosis and continuation of therapy, premedicated with methylprednisolone. *Dermatology*. 2002; 204:365-7. (IF 2.23)

National (refereed) journals

- Nijsten T, de Vries E. De epidemiologie van huidkanker en de gevolgen voor de zorg. *Nederlands Tijdschrift voor Oncologie*. In press 2010
- de Vries, E, Nijsten T, Louwman WJ, Coebergh JW. De feiten en cijfers achter de huidkankerepidemie in Nederland. *Ned Tijdschr Geneesk*. 2009;153:A768

Holterhues C , de Vries E, Nijsten T. De epidemiologie van huidkanker: zorg om de zorg. Nederlands Tijdschrift voor Dermatologie Venereologie. 2009, vol 19 nr 8.

Books, or contributions to books

Wakkee M, Nijsten T. De medicamenteuze behandeling van psoriasis. Farmacotherapie Online. Farmacotherapie Online. 2009. <http://www.farmacotherapie.org/home>

Van den Bos RR, Nijsten T. Endoveneuze behandelingstechnieken (chapter). Nederlands tekstboek voor Flebologie (2011)

Other

Wakkee M, Nijsten T. Psoriasis en obesitas, meer dan een toevallige combinatie (Psoriasis and obesity, more than an accidental combination). Modern Medicine. 2010:42-4.

Koomen ER, Joosse A, Herings RMC, Casparie MK, Bergman W, Nijsten T, Guchelaar HJG. Effecten van statines op huidmelanomen. Pharm Weekbl 2007, 42, 133-137.